BMS-345541
id:
bms-345541-192-5120248
title:
BMS-345541
text:
BMS-345541, developed by Merck KGaA, is an anti-inflammatory, cell-permeable quinoxaline compound. It is an allosteric site-binding inhibitor with a primary target of IKK-2 and blocks the NF-κB-dependent transcription in mice. It has no approvals for human/medical use or for use in clinical trials. No clinical trials mention it.
brand slug:
wiki
category slug:
encyclopedia
description:
Chemical compound
original url:
https://en.wikipedia.org/wiki/BMS-345541
date created:
date modified:
2023-12-20T19:52:48Z
main entity:
{"identifier":"Q4836000","url":"https://www.wikidata.org/entity/Q4836000"}
image:
{"content_url":"https://upload.wikimedia.org/wikipedia/commons/9/97/BMS-345541_structure.svg","width":512,"height":274}
fields total:
13
integrity:
15